Premium
Burden of illness in Parkinson's disease
Author(s) -
Huse Daniel M.,
Schulman Kathy,
Orsini Lucinda,
CastelliHaley Jane,
Kennedy Sean,
Lenhart Gregory
Publication year - 2005
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20609
Subject(s) - confidence interval , medicine , medical prescription , parkinson's disease , indirect costs , health care , total cost , disease , disease control , demography , pediatrics , emergency medicine , environmental health , accounting , sociology , economics , business , pharmacology , microeconomics , economic growth
Abstract This study quantifies direct medical care costs for individual patients with Parkinson's disease (PD) and projects total national costs of PD. Anonymous, patient‐level data on health care utilization and cost were obtained from Medstat's MarketScan Research Databases. Patients were selected for study if they had either two instances of a diagnosis of PD or one diagnosis and two or more prescriptions for PD‐related medication. A control group of persons without PD was selected for comparison. Total annual health care utilization and costs were calculated for both PD patients and controls. A total of 20,016 patients with PD were identified and followed up for an average of 853 days. The mean age of the patients was 73.6 years, and 51.2% were women. Total annual direct costs were $23,101 (SD 27,529) per patient with PD versus $11,247 (SD 16,486) for controls. The regression‐adjusted incremental direct cost of PD versus control was $10,349 (95% confidence interval, 9,053, 11,645). Adding $25,326 in indirect costs, and multiplying by 645,000 cases of PD in the United States, the total cost to the nation is projected to be $23 billion annually. This estimate is higher than most previous studies, with important implications for health care delivery systems worldwide. © 2005 Movement Disorder Society